aTyr Pharma is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its tRNA synthetase platform. aTyr’s lead therapeutic candidate, efzofitimod, is a novel immunomodulator in clinical development to resolve chronic inflammation and prevent the progression of fibrosis in interstitial lung disease (ILD). aTyr is currently conducting EFZO-FIT™, a global pivotal Phase 3 study of efzofitimod in pulmonary sarcoidosis, and EFZO-CONNECT™, Phase 2 study of efzofitimod in SSc-ILD.